Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey WT, Blüher M, Osorto Contreras CK, et al. (REDEFINE 1 Study Group) (2025). New England Journal of Medicine.
Summary
A 68-week phase 3a trial (REDEFINE 1) randomising 3,417 adults without diabetes to weekly cagrilintide plus semaglutide, semaglutide alone, cagrilintide alone, or placebo, alongside lifestyle intervention. Mean body-weight change was about -20% with the combination versus about -3% with placebo, and more participants on the combination reached weight-loss thresholds of 5% to 30%. Gastrointestinal adverse events were reported by about 80% of the combination group and about 40% of the placebo group, mostly transient and mild to moderate. Funded by Novo Nordisk.